N-Hydroxycytidine for Cell Culture

<strong>N-Hydroxycytidine for Cell Culture</strong>_x000D_ <strong>Catalog number:</strong> B2015966_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 5 mg_x000D_ <strong>Molecular Weight or Concentration:</strong> 259.22_x000D_ <strong>Supplied as:</strong> Powder_x000D_ <strong>Applications:</strong> a molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20 °C_x000D_ <strong>Keywords:</strong> N-Hydroxycytidine for cell culture, 98%_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Downs IL, David Ordonez Luna A, Kota KP, Rubin SK, Shirsekar SS, Ward MD, Panchal RG, Litosh VA. Modification of N-hydroxycytidine yields a novel lead compound exhibiting activity against the Venezuelan equine encephalitis virus Bioorg Med Chem Lett. 2023 Oct 1;94:129432._x000D_ 2: Clark NF, Taylor-Robinson AW, Heimann K. Could chlorophyllins improve the safety profile of beta-d-N4-hydroxycytidine versus N-hydroxycytidine, the active ingredient of the SARS-CoV-2 antiviral molnupiravir? Ther Adv Drug Saf. 2022 Jul 21;13:20420986221107753._x000D_ 3: Urakova N, Kuznetsova V, Crossman DK, Sokratian A, Guthrie DB, Kolykhalov AA, Lockwood MA, Natchus MG, Crowley MR, Painter GR, Frolova EI, Frolov I. β-d-N(4)-Hydroxycytidine Is a Potent Anti-alphavirus Compound That Induces a High Level of Mutations in the Viral Genome J Virol. 2018 Jan 17;92(3):e01965-17._x000D_ 4: Wallace KB, Bjork JA. Molnupiravir; molecular and functional descriptors of mitochondrial safety Toxicol Appl Pharmacol. 2022 May 1;442:116003._x000D_ 5: De Vito A, Colpani A, Bitti A, Zauli B, Meloni MC, Fois M, Denti L, Bacciu S, Marcia C, Maida I, Babudieri S, Madeddu G. Safety and efficacy of molnupiravir in SARS-CoV-2-infected patients: A real-life experience J Med Virol. 2022 Nov;94(11):5582-5588._x000D_ 6: Strizki JM, Gaspar JM, Howe JA, Hutchins B, Mohri H, Nair MS, Kinek KC, McKenna P, Goh SL, Murgolo N. Molnupiravir maintains antiviral activity against SARS-CoV-2 variants and exhibits a high barrier to the development of resistance Antimicrob Agents Chemother. 2024 Jan 10;68(1):e0095323._x000D_ 7: Nakamura K, Fujimoto K, Hasegawa C, Aoki I, Yoshitsugu H, Ugai H, Yatsuzuka N, Tanaka Y, Furihata K, Maas BM, Wickremasingha PK, Duncan KE, Iwamoto M, Stoch SA, Uemura N. A phase I, randomized, placebo-controlled study of molnupiravir in healthy Japanese to support special approval in Japan to treat COVID-19 Clin Transl Sci. 2022 Nov;15(11):2697-2708._x000D_ 8: Schaller MA, Sharma Y, Dupee Z, Nguyen D, Urueña J, Smolchek R, Loeb JC, Machuca TN, Lednicky JA, Odde DJ, Campbell RF, Sawyer WG, Mehrad B. Ex vivo SARS-CoV-2 infection of human lung reveals heterogeneous host defense and therapeutic responses JCI Insight. 2021 Sep 22;6(18):e148003._x000D_ 9: Gouda AS, Marzouk HM, Rezk MR, Salem AM, Morsi MI, Nouman EG, Abdallah YM, Hassan AY, Abdel-Megied AM. A validated LC-MS/MS method for determination of antiviral prodrug molnupiravir in human plasma and its application for a pharmacokinetic modeling study in healthy Egyptian volunteers J Chromatogr B Analyt Technol Biomed Life Sci. 2022 Aug 15;1206:123363._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/37267836">10: Gamal Fawzy M, Kamel EB. Sustainable Stability-Indicating spectra manipulations for the concurrent quantification of a novel Anti-COVID-19 drug and its active Metabolite: Green profile assessment Spectrochim Acta A Mol Biomol Spectrosc. 2023 Nov 5;300:122911. </a>_x000D_ _x000D_ <strong>Products Related to N-Hydroxycytidine for Cell Culture can be found at</strong> <a href="https://moleculardepot.com/product-category/Chemicals/"> Chemicals</a>